Isohormonal therapy of endocrine autoimmunity.
For most autoimmune disorders, the site (if any) of chronic immunization required for perpetuation of autoimmunity is unknown. However, one possible site is the target organ itself. If this were the case, feedback regulation of target cell activity might influence autoimmunity. Here, Nanette Schloot and George Eisenbarth review several recent studies suggesting that therapies that inhibit hormonal secretion of target endocrine organs, and/or modulate immunity by therapy with the isohormone, are associated with disease suppression.
Schloot
N
N
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver 80262, USA.
Eisenbarth
G S
GS
D000224:Addison Disease / Q000188:drug therapy / Q000276:immunology; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000235:genetics; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004700:Endocrine System Diseases / Q000188:drug therapy* / Q000276:immunology; D005246:Feedback; D006111:Graves Disease / Q000188:drug therapy / Q000276:immunology; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D051379:Mice; D016688:Mice, Inbred NOD; D009928:Organ Specificity; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D011913:Rats, Inbred BB; D013967:Thyroiditis, Autoimmune / Q000188:drug therapy / Q000276:immunology
D006728:Hormones; D007328:Insulin